[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342173-105":59,"doc-detail-342173-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","prognosis-prediction-using-significant-pathological-response-following-neoadjuvant-immunotherapy-in-resectable-non-small-cell-lung-tumors-a-meta-analysis","Prognosis prediction using signiﬁcant pathological response following neoadjuvant immunotherapy in resectable non-small-cell lung tumors - a meta-analysis","","A systematic meta-analysis evaluates how significant major pathological response can forecast outcomes in patients with resectable non-small-cell lung cancer (NSCLC) treated with neoadjuvant immunotherapy. Searches completed through August 2024 revise 2,386 connected studies, with 35 trials selected for 3,118 participants. Dichotomous techniques using fixed or random effects compute odds ratios and 95% confidence intervals for prediction based on major pathological response, objective response patterns, and PD-L1 status.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prognosis-prediction-using-significant-pathological-response-following-neoadjuvant-immunotherapy-in-resectable-non-small-cell-lung-tumors-a-meta-analysis/342173/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prognosis-prediction-using-significant-pathological-response-following-neoadjuvant-immunotherapy-in-resectable-non-small-cell-lung-tumors-a-meta-analysis/342173.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the primary aim of the meta-analysis?","Question",{"text":113,"@type":114},"To predict prognosis in patients with resectable NSCLC who achieved significant pathological response after neoadjuvant immunotherapy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which comparison showed higher major pathological response?",{"text":118,"@type":114},"Neoadjuvant chemo-immunotherapy produced significantly higher major pathological response than neoadjuvant chemotherapy.",{"name":120,"@type":111,"acceptedAnswer":121},"Did the meta-analysis find differences by stage or cancer histology?",{"text":122,"@type":114},"No significant differences were found between stage III versus stage I-II, and between squamous and non-squamous NSCLC.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},342173,1790291099,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","TYPE Systematic Review PUBLISHED 22 November 2024 DOI 10.3389/fsurg.2024.1500593  \nEDITED BY  \nGiulio Maurizi,  \nSapienza University of Rome, Italy  \nREVIEWED BY  \nMohamed Rahouma,  \nNewYork-Presbyterian, United States Filipe Azenha,  \nUniversity of Lucerne, Switzerland  \n*CORRESPONDENCE  \nRancen Tao  \n [taorancen@163.com](taorancen@163.com)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 23 September 2024  \nACCEPTED 04 November 2024  \nPUBLISHED 22 November 2024  \nCITATION  \nNie F, Wang Y, Shi W, Zhu L, Hao J and Tao R (2024) Prognosis prediction using signiﬁcant pathological response following neoadjuvant immunotherapy in resectable non-small-cell lung tumors: a meta-analysis.  \nFront. Surg. 11:1500593 .  \ndoi: 10.3389/fsurg.2024.1500593  \nCOPYRIGHT  \n© 2024 Nie, Wang, Shi, Zhu, Hao and Tao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPrognosis prediction using signiﬁcant pathological response following neoadjuvant immunotherapy in resectable non-small-cell lung tumors:  \na meta-analysis  \nFang Nie1†, Ying Wang2†, Wanting Shi1, Liru Zhu2, Jing Hao2 and Rancen Tao3*  \n1Thoracic Oncology Department, Baotou Cancer Hospital, Baotou, Inner Mongolia, China, 2Oncology and Palliative Care Department, Baotou Cancer Hospital, Baotou, Inner Mongolia, China, 3Thoracic Oncology Surgery Department, Baotou Cancer Hospital, Baotou, Inner Mongolia, China  \nBackground: A meta-analysis study was done to ﬁgure out how to predict the prognosis of people with resectable non-small-cell lung cancer (NSCLC) who had a signiﬁcant pathological response following neoadjuvant immunotherapy. Methods: Up until August 2024, a comprehensive literature study was completed, and 2,386 connected studies were revised. The 35 selected studies included 3,118 resectable non-small-cell lung tumor participants at the beginning of the study. Using dichotomous techniques and a ﬁxed or random model, the odds ratio (OR) and 95% conﬁdence intervals (CIs) were used to assess the prediction using signiﬁcant pathological response following neoadjuvant immunotherapy in resectable NSCLC.  \nResults: Individuals with resectable NSCLC had signiﬁcantly higher major pathological response when comparing neoadjuvant chemo-immunotherapy to neoadjuvant chemotherapy (OR, 5 . 07; 95% CI, 4 .09–6. 27, p \u003C 0 . 001), objective response rate to non-objective response rate (OR, 7.02; 95% CI, 4.28–11. 50, p \u003C 0 . 001), and programmed death-ligand 1 ≥1% to programmed death-ligand ≤1% (OR, 2 .49; 95% CI, 1 .44–4.30, p = 0 . 001) . However, no signiﬁcant difference was found in major pathological response between stage III and stage I-II (OR, 1 .43; 95% CI, 0 .88–2.33, p = 0 . 15), and squamous cell cancer and non-squamous cell cancer (OR, 1 .35; 95% CI, 0 .95–1. 92, p = 0 . 09) in individuals with resectable NSCLCs.  \nConclusion: Individuals with resectable NSCLCs had signiﬁcantly higher major pathological response when comparing neoadjuvant chemo-immunotherapy to neoadjuvant chemotherapy, objective response rate to non-objective response rate, and programmed death-ligand 1≥1% to programmed deathligand 1 ≤1%, however, no signiﬁcant difference was found between stage III and stage I-II, and squamous cell cancer and non-squamous cell cancer. To validate this discovery, more research is required since most of the selected studies had a low sample size, and caution must be implemented when interacting with its values.  \nKEYWORDS  \nresectable non-small-cell lung tumors, prognosis prediction, pathological response, programmed death-ligand 1, neoadjuvant immuno","cbCaid0iENkW8bpz","https://ap.wps.com/l/cbCaid0iENkW8bpz","pdf",4916481,13,"English","# Introduction\n## Treatment background and clinical rationale\n# Methods\n## Literature search and study selection\n## Statistical approach\n# Results\n## Major pathological response and response categories\n## PD-L1 subgroup comparisons\n## Stage and histology subgroup comparisons\n# Conclusion\n## Main findings and validation needs","[{\"question\":\"What was the primary aim of the meta-analysis?\",\"answer\":\"To predict prognosis in patients with resectable NSCLC who achieved significant pathological response after neoadjuvant immunotherapy.\"},{\"question\":\"Which comparison showed higher major pathological response?\",\"answer\":\"Neoadjuvant chemo-immunotherapy produced significantly higher major pathological response than neoadjuvant chemotherapy.\"},{\"question\":\"Did the meta-analysis find differences by stage or cancer histology?\",\"answer\":\"No significant differences were found between stage III versus stage I-II, and between squamous and non-squamous NSCLC.\"}]","Prognosis prediction using signiﬁcant pathological response following neoadjuvant immunotherapy in resectable non-small-cell lung tumors - a meta-analysis | PDF",1790045683,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14d877435b9b009f593aac7a897d83f9.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/553b08e02befd633caf7481a94a84097.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69e3a402ec7ce0b052f6fe6a783beacb.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cbf223a9523d9c7c4a2df41bc77be67b.webp",980,1385]